Bio-Techne (MEX:TECH) Cyclically Adjusted Revenue per Share: MXN107.38 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:TECH Bio-Techne Corp MEX:TECH
88 GF Score
Price MXN1,090.00
GF Value MXN1,072.06
! 7 Warning Signs
View Full Analysis

What is Bio-Techne Cyclically Adjusted Revenue per Share?

Bio-Techne MEX:TECH 88 Cyclically Adjusted Revenue per Share is MXN107.38 as of Jun. 2026. GuruFocus rates MEX:TECH with a GF Score™ of 88/100 and a GF Value™ of MXN1,072.06. The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Bio-Techne's adjusted revenue per share for the three months ended in Jun. 2026 was MXN35.650. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN107.38 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Bio-Techne's average Cyclically Adjusted Revenue Growth Rate was 8.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.30% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 11.50% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 12.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Bio-Techne was 15.80% per year. The lowest was 8.60% per year. And the median was 11.10% per year.

As of today (2026-09-03), Bio-Techne's current stock price is MXN1090.00. Bio-Techne's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was MXN107.38. Bio-Techne's Cyclically Adjusted PS Ratio of today is 10.15.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bio-Techne was 34.02. The lowest was 6.37. And the median was 14.03.


Bio-Techne  (MEX:TECH) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Bio-Techne's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1090.00/107.38
=10.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bio-Techne was 34.02. The lowest was 6.37. And the median was 14.03.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Bio-Techne Cyclically Adjusted Revenue per Share Related Terms


Bio-Techne Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Bio-Techne's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Techne Cyclically Adjusted Revenue per Share Chart

Bio-Techne Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 132.58 157.93 198.83 301.34 107.38

Bio-Techne Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 301.34 284.35 122.33 141.83 107.38

MEX:TECH vs SMMT, HALO, ARWR: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Bio-Techne's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio-Techne Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Techne's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Bio-Techne's Cyclically Adjusted PS Ratio falls into.


MEX:TECH
88GF Score
Bio-Techne Corp MEX:TECH
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bio-Techne Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Bio-Techne's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=35.65/333.9520*333.9520
=35.650

Current CPI (Jun. 2026) = 333.9520.

Bio-Techne Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 16.844 241.428 23.299
201612 18.127 241.432 25.074
201703 18.083 243.801 24.770
201706 18.848 244.955 25.696
201709 17.401 246.819 23.544
201712 19.957 246.524 27.035
201803 19.526 249.554 26.130
201806 23.047 251.989 30.543
201809 19.635 252.439 25.975
201812 22.108 251.233 29.387
201903 23.069 254.202 30.306
201906 23.523 256.143 30.669
201909 23.040 256.759 29.967
201912 22.047 256.974 28.651
202003 28.939 258.115 37.442
202006 25.660 257.797 33.240
202009 28.176 260.280 36.151
202012 27.702 260.474 35.517
202103 30.598 264.877 38.577
202106 31.427 271.696 38.628
202109 32.188 274.310 39.186
202112 33.513 278.802 40.142
202203 35.281 287.504 40.981
202206 35.448 296.311 39.951
202209 33.447 296.808 37.633
202212 32.734 296.797 36.832
202303 32.806 301.836 36.297
202306 31.865 305.109 34.877
202309 29.788 307.789 32.320
202312 28.909 306.746 31.473
202403 31.376 312.332 33.548
202406 34.908 314.175 37.105
202409 35.375 315.301 37.468
202412 38.567 315.605 40.809
202503 40.697 319.799 42.498
202506 38.042 322.561 39.385
202509 33.618 324.800 34.565
202512 33.933 324.054 34.969
202603 35.677 330.213 36.081
202606 35.650 333.952 35.650

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN107.38 mean?
Bio-Techne (MEX:TECH) has a Cyclically Adjusted Revenue per Share of MXN107.38 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bio-Techne and its competitors.
Is Bio-Techne's Cyclically Adjusted Revenue per Share too high?
Bio-Techne's current Cyclically Adjusted Revenue per Share is MXN107.38. Overall, Bio-Techne has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does Bio-Techne's Cyclically Adjusted Revenue per Share compare to SMMT and HALO?
Bio-Techne's Cyclically Adjusted Revenue per Share of MXN107.38 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bio-Techne and its competitors. Bio-Techne's current Cyclically Adjusted Revenue per Share is MXN107.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Techne stock overvalued right now?
Bio-Techne (MEX:TECH) has a current Cyclically Adjusted Revenue per Share of MXN107.38. The stock's GF Value™ is MXN1,072.06, compared to a current price of MXN1,090.00 — trading 1.7% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN107.38. Bio-Techne's overall GF Score™ is 88/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Bio-Techne (MEX:TECH), the current Cyclically Adjusted Revenue per Share is MXN107.38 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bio-Techne (MEX:TECH) Overvalued in 2026?

Based on GuruFocus' analysis, Bio-Techne stock appears to be overvalued. The current stock price of MXN1,090.00 is trading 1.7% above its estimated GF Value™ of MXN1,072.06.

Key valuation signals for MEX:TECH:

  • Cyclically Adjusted Revenue per Share: MXN107.38
  • GF Value™: MXN1,072.06 vs. price of MXN1,090.00 (1.7% above fair value)
  • GF Score™: 88/100 with 7 warning signs

No single metric tells the full story. See the MEX:TECH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bio-Techne Business Description

Address 614 McKinley Place N.E., Minneapolis, MN, USA, 55413
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
88GF Score

Get the complete analysis for MEX:TECH

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,090.00
Price
MXN1,072.06
GF Value